β-Blockers and their mortality benefits: Underprescribed in heart failure and chronic obstructive pulmonary disease

Future Cardiology

Volumn 7, Issue 1, 2011, Pages 43-53

  Rutten, Frans H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

blockers; adverse effect; chronic obstructive pulmonary disease; heart failure; pathways

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL SUCCINATE;

AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DIZZINESS; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; FATIGUE; HEART BLOCK; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RAYNAUD PHENOMENON;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NETHERLANDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 78650639439     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.119     Document Type: Article

References (99)

1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic b-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. 37, 1022-1036 (1975).
2. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I: Prolongation of survival in congestive cardiomyopathy by b-receptor blockade. Lancet 1, 1374-1376 (1979).
3. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342, 1441-1446 (1993).
4. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 28, 2539-50 (2008).
5. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA: Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 113, 1489-1494 (1987).
6. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R: Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372, 817-821 (2008).
7. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875-885 (2010).
8. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376, 886-894 (2010).
9. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 50, 823-830 (2007).
10. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/Trandolapril Study (INVEST). Eur. Heart J. 29, 1327-1334 (2008).
11. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. b-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J. Am. Coll. Cardiol. 53, 2150-2158 (2009).
12. Aronow WS, Ahn C, Kronzon I: Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ?40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am. J. Cardiol. 80, 207-209 (1997).
13. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777-781 (2003).
14. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur. Heart J. 27, 2338-2345 (2006).
15. Hori M, Kitabatake A, Tsutsui H, et al. Rationale and design of a randomized trial to assess the effects of b-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). J. Card. Fail. 11, 542-547 (2005).
16. DiFrancesco D, Camm JA: Heart rate lowering by specific and selective I(f ) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64, 1757-1765 (2004).
17. Waagstein F, Stromblad O, Andersson B, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 5, 679-691 (2003).
18. Ramahi TM, Longo MD, Cadariu AR, et al. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after b-blocker therapy in nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 37, 818-824 (2001).
19. Reil JC, Reil GH, Bohm M. Heart rate reduction by I(f )-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc. Med. 19, 152-157 (2009).
20. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: b-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 150, 784-794 (2009).
21. Flannery G, Gehrig-Mills R, Billah B, Krum H: Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving b-blockers. Am. J. Cardiol. 101, 865-869 (2008).
22. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103, 1428-1433 (2001).
23. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with b-adrenergic blockade. J. Am. Coll. Cardiol. 25, 1154-1161 (1995).
24. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355 (1996).
25. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
26. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
27. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001). (Pubitemid 32479962)
28. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215-225 (2005).
29. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 289, 712-718 (2003).
30. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 349, 375-380 (1997).
31. CIBIS Investigators and Committees: A randomized trial of b-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90, 1765-1773 (1994).
32. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7-13 (2003).
33. Goldstein S. Benefits of b-blocker therapy for heart failure: weighing the evidence. Arch. Intern. Med. 162, 641-648 (2002).
34. The b-Blocker Evaluation of Survival Trial (BEST) Investigators: A trial of the b-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667 (2001).
35. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112, 2426-2435 (2005).
36. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94, 2807-2816 (1996).
37. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J. Am. Coll. Cardiol. 40, 491-498 (2002). (Pubitemid 34833165)
38. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. 24, 464-474 (2003). (Pubitemid 36286188)
39. Cleland JG, Cohen S, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360, 1631-1639 (2002).
40. Patel P, White DL, Deswal A: Translation of clinical trial results into practice: temporal patterns of b-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am. Heart J. 153, 515-522 (2007).
41. Shah SM, Carey IM, DeWilde S, Richards N, Cook DG: Trends and inequities in b-blocker prescribing for heart failure. Br. J. Gen. Pract. 58, 862-869 (2008).
42. Teerlink JR: Ivabradine in heart failure - no paradigm SHIFT yet. Lancet 376, 847-849 (2010).
43. Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur. Heart J. 26, 1653-1659 (2005).
44. Schuchert A: Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. Eur. J. Heart Fail. 7, 604-611 (2005).
45. Krum H, Ninio D, MacDonald P: Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 84, 615-619 (2000).
46. Fowler MB, Lottes SR, Nelson JJ, et al. b-blocker dosing in community-based treatment of heart failure. Am. Heart J. 153, 1029-1036 (2007).
47. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two b-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J. Hypertens. 14, 489-494 (1996).
48. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99, 2645-2651 (1999).
49. Paravastu SC, Mendonca DA, da Silva A: b blockers for peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg. 38, 66-70 (2009).
50. Gheorghiade M, Colucci WS, Swedberg K: b-blockers in chronic heart failure. Circulation 107, 1570-1575 (2003).
51. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med. 126, 955-959 (1997).
52. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357, 1385-1390 (2001).
53. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur. J. Heart Fail. 8, 706-711 (2006).
54. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur. J. Heart Fail. 11, 130-139 (2009).
55. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur. Heart J. 26, 1887-1894 (2005).
56. Rutten FH, Vonken EJ, Cramer MJ, et al. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. Am. Heart J. 156, 506-512 (2008).
57. Naeije R: Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 20-22 (2005).
58. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad. Emerg. Med. 10, 198-204 (2003).
59. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur. J. Heart Fail. 11, 1182-1188 (2009).
60. Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P: Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am. Heart J. 155, 521-525 (2008).
61. De BJ, Simard S, Atar D, Agewall S. COPD predicts mortality in HF. the Norwegian Heart Failure Registry. J. Card. Fail. 16, 225-229 (2010).
62. Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates C: Cardioselective b-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2, CD003566 (2002).
63. Salpeter S, Ormiston T, Salpeter E: Cardioselective b-blockers for reversible airway disease. Cochrane Database Syst. Rev. 4, CD002992 (2002).
64. Cazzola M, Matera MG: b-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. Am. J. Respir. Crit. Care Med. 178, 661-662 (2008).
65. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR: Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J. Heart Lung Transplant. 21, 1290-1295 (2002).
66. Ormiston TM, Salpeter SR: b-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. Heart Fail. Monit. 4, 45-54 (2003).
67. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between b-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J. Am. Coll. Cardiol. 55, 1780-1787 (2010).
68. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur. J. Heart Fail. 11, 684-690 (2009).
69. Hawkins NM, Jhund PS, Simpson CR, et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur. J. Heart Fail. 12, 17-24 (2010).
70. Shelton RJ, Rigby AS, Cleland JG, Clark AL: Effect of a community heart failure clinic on uptake of b blockers by patients with obstructive airways disease and heart failure. Heart 92, 331-336 (2006).
71. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007).
72. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
73. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107, 1514-1519 (2003).
74. Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD. role of comorbidities. Eur. Respir. J. 28, 1245-1257 (2006).
75. Hole DJ, Watt GC, Davey S, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996, 313, 711-715.
76. Harries AD. b-blockade in asthma. BMJ 282, 1321 (1981).
77. Barnes PJ. Non-adrenergic non-cholinergic neural control of human airways. Arch. Int. Pharmacodyn. Ther. 280(2 Suppl.), 208-228 (1986).
78. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 129, 856-870 (1984).
79. Gottlieb SS, McCarter RJ, Vogel RA: Effect of b-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 339, 489-497 (1998).
80. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of b-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J. Am. Coll. Cardiol. 37, 1950-1956 (2001).
81. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective b-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am. J. Respir. Crit. Care Med. 178, 695-700 (2008).
82. Andreas S, Anker SD, Scanlon PD, Somers VK: Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128, 3618-3624 (2005).
83. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. b-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 170, 880-887 (2010).
84. Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting b2-agonists arformoterol and salmeterol. Medicine 87, 319-328 (2008).
85. Levine HJ. Rest heart rate and life expectancy. J. Am. Coll. Cardiol. 30, 1104-1106 (1997).
86. Lin R, Peng H, Nguyen LP, et al. Changes in b2-adrenoceptor and other signaling proteins produced by chronic administration of b-blockers in a murine asthma model. Pulm. Pharmacol. Ther. 21, 115-124 (2008).
87. Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of b-adrenoceptor ligands on airway function in a murine model of asthma. Proc. Natl Acad. Sci. USA 101, 4948-4953 (2004).
88. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA: Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 153, 1802-1811 (1996).
89. Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to b-blockers attenuates inflammation and mucin content in a murine asthma model. Am. J. Respir. Cell. Mol. Biol. 38, 256-262 (2008).
90. Sin DD, Man SF. A curious case of b-blockers in chronic obstructive pulmonary disease. Arch. Intern. Med. 170, 849-850 (2010).
91. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 47, 2554-2560 (2006).
92. Soyseth V, Brekke PH, Smith P, Omland T: Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 29, 279-283 (2007).
93. Au DH, Bryson CL, Fan VS, et al. b-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am. J. Med. 117, 925-931 (2004).
94. McAinsh J, Cruickshank JM. b-blockers and central nervous system side effects. Pharmacol. Ther. 46, 163-197 (1990).
95. Radack K, Deck C: b-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch. Intern. Med. 151, 1769-1776 (1991).
96. Fonarow GC: Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am. J. Med. 116(Suppl. 5A), 76S-88S (2004).
97. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28, 88-136 (2007).
98. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 29, 8-14 (1997).
99. Shiri R, Koskimaki J, Hakkinen J, Auvinen A, Tammela TL, Hakama M. Cardiovascular drug use and the incidence of erectile dysfunction. Int. J. Impot. Res. 19, 208-212 (2007).